Molecular subtypes of pancreatic cancer

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

Pancreatic Cancer

Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732

Heterogeneity-Preserving Discriminative Feature Selection for Disease-Specific Subtype DiscoveryPreprint

Basher, A. R. M. A., Hallinan, C., & Lee, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.14.540686 · Cited by 1

The integration of Tgfβ and Egfr signaling programs confers the ability to lead heterogeneous collective invasionPreprint

Nasir, A., Camacho, S., McIntosh, A. T., Graham, G. T., Rahhal, R., Huysman, M. E., Alsharief, F., Riegel, A. T., & Pearson, G. W. (2023) · doi:10.7554/elife.87991 · Cited by 1

Molecular Understanding of the Development of Ductal Pancreatic Cancer

Lee, J. W., Hruban, R. H., & Wood, L. D. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch119 · Cited by 1

From Tissue Turnover to the Cell of Origin of Pancreatic Cancer

Kong, B., Thoma, E., & Michalski, C. W. (2023) · doi:10.1002/9781119876007.ch120 · Cited by 1

Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal AdenocarcinomaPreprint

Zhang, X., Lan, R., Liu, Y., Pillarisetty, V. G., Li, D., Zhao, C. L., Sarkar, S. A., Liu, W., Hanna, I. T., Gupta, M. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.26.564099 · Cited by 1

Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNAPreprint

Lueong, S., Metzenmacher, M., Trajkovic‐Arsic, M., Cheung, P. F., Reißig, T. M., Neuhoff, N. V., Grainne, O., Gallinger, S., Ramotar, S., Dodd, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3688314/v1 · Cited by 1

nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancerPreprint

Hendley, A. M., Ashe, S., Urano, A., Ng, M., Phu, T. A., Peng, X. L., Luan, C., Finger, A., Jang, G. H., Kerper, N. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.23.614610 · Cited by 1

Plasminogen activator inhibitors orchestrate the immunosuppressive tumor microenvironment in pancreatic cancerPreprint

Falcomatà, C., Nielsen, S. R., Schaefer, M. M., Singh, B., Tepper, A., Chhamalwan, D., Potak, H. T., Dhainaut, M., Mollaoglu, G., Park, M. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.659098 · Cited by 1

Pathologie des PDAC: Übersicht und Neues

Schlitter, A. M., Kasajima, A., Groß, C., Konukiewitz, B., & Klöppel, G. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6744-1

Schnittbilddiagnostik beim duktalen Adenokarzinom des Pankreas

Lohöfer, F. K., Kaissis, G. A., & Braren, R. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6745-0

Pathologische Standards in der Befundung von Biopsien und Operationspräparaten mit Bauchspeicheldrüsenkrebs

Oberhuber, G., Steinle, H., Oberhuber, M., & Stättner, S. (2019) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-019-00062-5

Detection of Chemotherapy-Resistant Pancreatic Cancer Using a Glycan BiomarkerPreprint

Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.01.128082

Anotação e caracterização de novos transcritos expressos no adenocarcinoma de pâncreas: RNAS não-codificadores longos associados a fenótipos tumorais e clínicos e formas alternativas de splicing

da Paixão, V. F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2019.tde-09032020-085211

Cancer genomic profiling

Hayashi, H., & Nishihara, H. (2020) · Suizo · doi:10.2958/suizo.35.313

Improving Outcomes in Pancreatic Cancer

Sharman, R., & Shroff, R. T. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.59

TNM Staging for Pancreatic Adenocarcinoma

Roalsø, M. T. T., & Søreide, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_25

Role of Stroma in Pancreatic Cancer

Sund, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_18

Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes

Hwang, J. W., Jang, S. K., & Lee, D. J. (2021) · Medicine · doi:10.1097/md.0000000000024969

New Pharmacological Approaches for Pancreatic Cancer Therapy

Gupta, V. K., Banerjee, S., & Saluja, A. K. (2021) · doi:10.1002/9781119570097.ch69

Precision Medicine for Pancreatic Cancer

Kim, R. Y., Evans, D. B., & Tsai, S. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.006

Analysis on the Treatments on Early Diagnosis of Pancreatic Cancer (PC)

Zhang, J. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127103052

Risk Factors for Pancreatic Cancer and Cholangiocarcinoma

Hamada, T., & Nakai, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_1

Cpg Island Methylator Phenotype With Distinctly Different Prognosis And Molecular Features In Pancreatic Cancer PatientPreprint

Ning, G., Li, Y., Chen, W., Tang, W., Shou, D., Luo, Q., Chen, H., & Zhou, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-153446/v1

Tracing tumor evolution and subtype specification in pancreatic cancerPreprint

Rajbhandari, N., Hamilton, M., Quintero, C. M., Ferguson, L. P., Fox, R., Schürch, C. M., Wang, J., Nakamura, M., McDermott, M. L., Pettit, H. W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-101578/v1

Fosfatases de dupla especificidade interferem na resposta de células de adenocarcinoma ductal pancreático ao tratamento com gemcitabina

Vieira, G. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-04082021-130011

[The pros and cons of femoral artery disobliteration].

Balzer, K. M., & Carstensen, G. (1982) · PubMed

Collapsin Response Mediator Protein 1 Acts as a Tumor Suppressor in Pancreatic Cancer Mediated by AXIN1/ β-Catenin Signaling AxisPreprint

Lei, Y., Tan, Z., He, X., Xu, J., Liang, C., Meng, Q., Hua, J., Liu, J., Zhu, H., Wang, W., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3989797

Overcoming Cisplatin Resistance in Pancreatic Cancer

Ewers, K. M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8945

GSK3β-mediated DNA damage repair in pancreatic cancer

Schmídt, G. (2021) · doi:10.53846/goediss-8509

Identification of Molecular Subgroups in Liver Cirrhosis by Gene Expression Profiles

Zhang, Y., Sun, F., Li, X., Liu, Q., Chen, Z.-M., & Guo, Y. (2022) · Hepatitis Monthly · doi:10.5812/hepatmon.118535

A ferroptosis-related signature for predicting prognosis and immunotherapy response in cervical squamous carcinomaPreprint

Yang, Y., Fu, X., & Yang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1478458/v1

Faculty Opinions recommendation of Cell of origin influences pancreatic cancer subtype.

Sosa‐Pineda, B. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739647870.793585324

The Germline/somatic DNA Damage Repair Gene Mutations Modulate the Therapeutic Response in Chinese Patients With Advanced Pancreatic Ductal AdenocarcinomaPreprint

Shui, L., Li, X., Yang, P., Tian, J., Li, S., He, D., Li, A., Tian, B., Mao, L., Yi, C., et al. (2020) · doi:10.21203/rs.3.rs-60530/v1

Ultra-small bispecific fusion protein augments tumor penetration and treatment efficacy for pancreatic cancerPreprint

Wang, Q., Wang, J., Yan, H., Li, Z., Wang, K., Kang, F., Tian, J., & Zhao, X. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.17.492287

A ferroptosis-related signature for predicting prognosis and immunotherapy response in cervical squamous carcinomaPreprint

Yang, Y., Fu, X., & Yang, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1478458/v2

Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options

Tempero, M. A. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.5005

Pathology of Pancreatic Cancer

Hruban, R. H., & Thompson, E. D. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_12

S100A2 and the Np63 Network, an overlooked pancreatic cancer drug target

Scarlett, C. J. (2022) · GCISTEM Proceeding · doi:10.56573/gcistem.v1i.28

The role of the ROBO 3 signaling pathway in pancreatic cancer plasticity

Krebs, N. (2022) · doi:10.53846/goediss-9412

Transcriptionally defined morphological subtypes of pancreatic ductal adenocarcinomaPreprint

Krieger, T. G., Sudy, A., Schicktanz, F., Tosti, L., Liebig, J., Konukiewitz, B., Rouault, M., Niesnerova, A., Qian, X., Weichert, W., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.23.509133

Prognosis and personalized treatment prediction of IGF2BP2- mediated m6A modification patterns in pancreatic cancerPreprint

Chen, D., Zang, L., Gao, W., Zhang, X., Li, Z., Shu, Y., Zhu, H., & Yu, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2420342/v1

Proteogenomic analysis of human pancreatic ductal adenocarcinoma

(2023) · Nature Cancer · doi:10.1038/s43018-022-00478-8

Recommendation: Treatment of pancreatic cancer in 2022 — R1/PR8

(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr8

Decision: Treatment of pancreatic cancer in 2022 — R1/PR9

(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr9

Review: Treatment of pancreatic cancer in 2022 — R1/PR7

(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr7

Author comment: Treatment of pancreatic cancer in 2022 — R1/PR6

Casolino, R. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr6

Decision: Treatment of pancreatic cancer in 2022 — R0/PR5

(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr5

Recommendation: Treatment of pancreatic cancer in 2022 — R0/PR4

(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr4

Review: Treatment of pancreatic cancer in 2022 — R0/PR2

(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr2

Review: Treatment of pancreatic cancer in 2022 — R0/PR3

(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr3

Author comment: Treatment of pancreatic cancer in 2022 — R0/PR1

Casolino, R. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr1

Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia

(2023) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477275-07

Data from Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress

Tomihara, H., Carbone, F., Perelli, L., Huang, J. K.-L., Soeung, M., Rose, J. L., Robinson, F. S., Deribe, Y. L., Feng, N., Takeda, M., et al. (2023) · doi:10.1158/0008-5472.c.6512376.v1

Data from Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics

Topham, J. T., Karasinska, J. M., Lee, M. K. C., Csizmók, V., Williamson, L., Jang, G. H., Denroche, R. E., Tsang, E. S., Kalloger, S. E., Wong, H., et al. (2023) · doi:10.1158/1078-0432.c.6529866

Data from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples

Semaan, A., Bernard, V., Lee, J. J., Wong, J., Huang, J. H., Swartzlander, D. B., Stephens, B. M., Monberg, M. E., Weston, B. R., Bhutani, M. S., et al. (2023) · doi:10.1158/1078-0432.c.6530151

Data from A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry

Son, M., Kim, H., Han, D., Kim, Y., Huh, I., Han, Y., Hong, S., Kwon, W., Kim, H., Jang, J., et al. (2023) · doi:10.1158/1078-0432.c.6530268.v1

Data from Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies

Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J. H., Stephens, B. M., Lin, D., Rajapakshe, K., Weston, B. R., Bhutani, M. S., et al. (2023) · doi:10.1158/1078-0432.c.6530469.v1

Data from Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy

Sinnett‐Smith, J. W., Anwar, T., Reed, E. F., Teper, Y., Eibl, G., & Rozengurt, E. (2023) · doi:10.1158/1535-7163.c.6543589

Data from Cell of Origin Influences Pancreatic Cancer Subtype

Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H. S., Curtis, C. N., Wood, L. D., & Attardi, L. D. (2023) · doi:10.1158/2159-8290.c.6547895.v1

Preserved correlation matrices pinpoint extracellular matrix organization as a critical factor in pancreatic ductal adenocarcinoma

Menyhárt, O., Bartha, Á., & Győrffy, B. (2023) · F1000Research · doi:10.12688/f1000research.131414.1

Fosfatase atípica DUSP11 regula a morte celular induzida pela gemcitabina por meio da ativação da via NF-κB em células de carcinoma pancreático

Santos, V. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-08052023-143100

Biomarkers for Pancreatic Cancer: Going Beyond the Impossible?

Ansari, D., & Andersson, R. E. (2022) · doi:10.58974/bjss/azbc005

The integration of Tgfβ and Egfr signaling programs confers the ability to lead heterogeneous collective invasionPreprint

Nasir, A., Camacho, S., McIntosh, A. T., Graham, G. T., Rahhal, R., Huysman, M. E., Alsharief, F., Riegel, A. T., & Pearson, G. W. (2023) · doi:10.7554/elife.87991.1

Pathology, Pathogenesis, and Molecular Characteristics

Chun, H. J., Park, S. J., Lim, Y. J., & Song, S. Y. (2023) · Springer eBooks · doi:10.1007/978-981-99-0815-8_49

Machine learning algorithm integrates bulk and single-cell transcriptome sequencing to reveal immune-related personalized therapy prediction features for pancreatic cancerPreprint

Zang, L., Zhang, B., Zhou, Y., Zhang, F., Tian, X., Tian, Z., Chen, D., & Miao, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3137621/v1

Kinase Activities in Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic AvenuesPreprint

Vallés‐Martí, A., de Haas, R. R. D. G., Henneman, A. A., Piersma, S. R., Pham, T. V., Knol, J. C., Verheij, J., Dijk, F., Halfwerk, H., Giovannetti, E., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4506560

The role of cellular immunity in the treatment of cancer

Στραβοκεφάλου, Β. (2023) · doi:10.12681/eadd/54076

Identification of Molecular Subtypes and Prognostic Signature Based on Panoptosis-Related Genes in Pancreatic AdenocarcinomaPreprint

Lin, Y., Wei, T., Fang, Q., Tong, H., Tu, B., Zeng, J., Jiang, F., & Du, M. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4513145

The Role of Endoscopic Ultrasonography in the Diagnosis and Differential Diagnosis of Neoplastic Lesions

Hirooka, Y., Hashimoto, S., & Ohno, E. (2023) · doi:10.1002/9781119876007.ch128

Targeted Therapies for Pancreatic Cancer

Maitra, A. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch151

Molecular Subtypes and Clinical Applications

Bijlsma, M. F., & Bailey, P. J. (2023) · doi:10.1002/9781119876007.ch122

Estudo da atividade biológica de inibidores de cisteíno catepsinas antineoplásicos em linhagens celulares de câncer de pâncreas (MIA PaCa-2 e BxPC-3)

Laroca, B. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.82.2022.tde-10102023-093131

A novel defined cuproptosis-related signature for predicting prognosis and immunotherapy efficacy in pancreatic cancerPreprint

Ge, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3488284/v1

Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker?

Rivière, D., Aarntzen, E. H. J. G., van Geenen, E., Chang, D. K.-F., de Geus‐Oei, L., Brosens, L. A. A., van Laarhoven, C. J. H. M., Gotthardt, M., & Hermans, J. J. (2023) · HPB · doi:10.1016/j.hpb.2023.11.010

Obesity Is Associated with Distal Migration of Pancreatic Adenocarcinoma to Body and Tail: A Multi-Center Study

Sbeit, W., Gershovitz, G., Shahin, A., Shhadeh, S., Salman, M., Basheer, M., & Khoury, T. (2024) · Cancers · doi:10.3390/cancers16020359

Recent advancement in molecular markers of pancreatic cancer

Paul, L. T. D., Munuswamy‐Ramanujam, G., Kumar, R. C. S., Ramachandran, V., Gnanasampanthapandian, D., & Palaniyandi, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00025-x

Patient Subtyping Analysis of Baseline Multi-omic Data Reveals Distinct Pre-immune States Predictive of Vaccination ResponsesPreprint

Bayrak, Ç. S., Forst, C. V., Jones, D. R., Gresham, D., Pushalkar, S., Wu, S., Vogel, C., Mahal, L. K., Ghedin, E., Ross, T. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.18.576213

Pathology, Molecular Pathology, and Genomics of Hepatobiliary and Pancreatic Cancer

Mróz, A. (2024) · doi:10.1002/9781119756422.ch15

Identification of the Genetic Association Between Ferroptosis and immune in Pancreatic CancerPreprint

Zhang, X., Liu, P., Fu, Q., Liu, C., Luo, Q., Yu, P., Bian, J., Pan, C., Zhang, H., & Qin, T. (2024) · Research Square · doi:10.21203/rs.3.rs-3927756/v1

Hourglass, a compass navigating global and regional heterogeneity of pancreatic cancer †

Bakırdöğen, D., Görgülü, K., & Algül, H. (2024) · The Journal of Pathology · doi:10.1002/path.6268

A distinctive tumor compartment in pancreatic lobules defined by nascent stroma and classical tumor cell phenotypePreprint

Söderqvist, S., Viljamaa, A., Geyer, N., Strell, C., Hekmati, N., Engstrand, J., Sparrelid, E., Salmén, C., Heuchel, R. L., Zacharouli, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.584614

Additional file 2 of Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy

Liu, J., Liu, Q., Zhang, X., Cui, M., Li, T., Zhang, Y., & Liao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.14129388

Pancreatic Cancer

Annamaraju, S. S., Mullaguri, S. C., Putta, S., Vishnubhotla, R., & Kancha, R. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-1802-3_7

Targeting mucins for fluorescence-guided surgery of pancreatic cancer

Mohs, A. M., Muilenburg, K. M., & Ehrhorn, E. G. (2024) · Molecular-Guided Surgery: Molecules, Devices, and Applications · doi:10.1117/12.3009900

Preoperative chemotherapy plus immune checkpoint inhibitors as conversion therapy in pancreatic cancer patients with initially unresectable liver-limited metastases: a case report

Xiao, L., Zhang, H., Tan, C., Liu, X., & Zheng, Z. (2024) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000189

Exploring the Influence of c-Jun N terminal Kinase Scaffold Proteins on the Spatiotemporal Regulation of JNK Activation in Pancreatic Ductal AdenocarcinomaPreprint

Kadir, S., & Chowdhury, T. A. (2024) · Research Square · doi:10.21203/rs.3.rs-4792346/v1

Clonal evolutionary analysis reveals patterns of malignant transformation in pancreatic cancer from Intraductal Papillary Mucinous IPMN Neoplasms (IPMN)Preprint

Pea, A., He, X. T., Upstill‐Goddard, R., Luchini, C., Santana, L. P. S., Dreyer, S. B., Duthie, F. R., Jamieson, N. B., McKay, C. J., Dickson, E. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.02.606217

Bioinformatical and experimental validation on EFNA5 biomarker for pancreatic cancer

Hua, Z., Zhao, R., Guan, W., Liu, S., Ge, J., Zhang, Y., Khan, S., Pan, Z., & Wang, J. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105990

Fatty Acid Synthase (Fasn) Inhibition Cooperates with Bh3 Mimetic Drugs to Overcome Resistance to Mitochondrial Apoptosis in Pancreatic CancerPreprint

Menéndez, J. A., Steen, T. V., Espinoza, I. C., Duran, C., Casadevall, G., Serrano‐Hervás, E., Cuyàs, E., Verdura, S., Kemble, G. W., Kaufmann, S. H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4948747

MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

Muilenburg, K. M., Ehrhorn, E. G., Olson, M. T., Isder, C. C., Klute, K. A., Talmon, G. A., Carlson, M. A., Ly, Q. P., & Mohs, A. M. (2024) · Cancers · doi:10.3390/cancers16203439

Genome-scale activation screen reveals lncRNA HNF1A-AS1 as a novel therapeutic target for pancreatic cancer metastasisPreprint

Lei, S., Zhang, Z., Zeng, Z., Cao, W., Sun, Y., Li, D., Pan, J., Wu, Y., Zhang, T., & Chen, T. (2024) · Research Square · doi:10.21203/rs.3.rs-5388928/v1

Exploring the Influence of c-Jun N terminal Kinase Scaffold Proteins on the Spatiotemporal Regulation of JNK Activation in Pancreatic Ductal AdenocarcinomaPreprint

Kadir, S., Chowdhury, T. A., ParthaLaskar, & Chauhan, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4792346/v2

Effect of Stroma-directed Drugs in Combination with Chemotherapy Against Pancreatic Cancer- a Preclinical StudyPreprint

Gupta, M., Choi, H., Furth, E. E., Shaffer, S. M., Pickup, S., Clendenin, C., Liu, F., Cao, Q., Song, H. K., Yong Fan, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.24.630138

Histopathological Changes in Pancreatic Cancer: A Review Article

Al-Harbi, S. J., & Al-fahham, A. A. (2025) · INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH · doi:10.58806/ijhmr.2025.v4i1n05

DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells

Leccese, A., Ruta, V., Panzeri, V., Attili, F., Spada, C., Cianfanelli, V., & Sette, C. (2025) · Cancers · doi:10.3390/cancers17040570

Expression of SMURF family in pancreatic cancer and its effect on cell proliferation and migration

Zhang, C., Li, C., Wu, L., Wang, Y., Huang, K., Yang, X., Zhao, S., Zhu, H., Shi, L., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1538335

SNHG10 promote tumorigenesis via miR-150/VEGFA/EGFR/AKT/ERK/mTOR axis and gemcitabine resistance in PDACPreprint

Pandya, G., Singh, A. P., Sourav, S., Raju, S., Kumari, R., Sharma, R., Goyal, V., Das, B. C., Sethi, G., Pandey, A. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650424

Contemporary insights into the molecular mechanisms of development and genetic susceptibility to pancreatic cancer

Speridonova, A. D., Zaripova, A. R., Gilyazova, I. R., & Bermisheva, M. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2025-24-3-149-161

Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort

Lü, H., He, Q., Cao, Y., Liu, C., & Li, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1636715

Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells

Dutta, D., Upadhyay, S. P., De, A., Haque, I., Breier, A. H., De, A., Mettman, D. J., Kambhampati, S., Quadir, M., DÍAZ, F. J., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201047

Molecular Subtyping of Pancreatic Cancer

Dreyer, S. B., Jamieson, N. B., Chang, D. K.-F., & Biankin, A. V. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_21 · Cited by 1

Molecular Subtyping and Precision Medicine for Pancreatic Cancer

Froeling, F. E. M., Casolino, R., Pea, A., Biankin, A. V., Chang, D. K.-F., & Precision-Panc, O. B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10010149 · Cited by 52

Abstract I08: Molecular subtypes - bench to bedside

Yeh, J. J. (2019) · Cancer Research · doi:10.1158/1538-7445.panca19-i08

Subtyping for pancreatic cancer precision therapy

Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 32

Current research status and progress in molecular subty-ping of pancreatic cancer

Yang, Y., & Zhang, Z. (2019) · Zhōnghuá xiāohuà wàikē zázhì/Zhonghua xiaohua waike zazhi · doi:10.3760/cma.j.issn.1673-9752.2019.07.002